By Abigail Summerville (Reuters) – Private equity-backed Roland Foods is exploring a sale that could value the specialty food provider at $700 million or more, including debt, people familiar wi[...]
Read more
January 31, 2024
At Japan Airlines, bankruptcy helped lay groundwork for first female boss
By Maki Shiraki and Anton Bridge TOKYO (Reuters) – The seeds of former flight attendant Mitsuko Tottori’s rise to the top of Japan Airlines (JAL) were planted in the aftermath of the carri[...]
Read more
Slowing US labor cost gains brighten inflation picture
By Lucia Mutikani WASHINGTON (Reuters) – U.S. labor costs rose less than expected in the fourth quarter and the annual increase was the smallest in two years, signs of moderating wage inflation[...]
Read more
Judge voids Elon Musk’s ‘unfathomable’ $56 billion Tesla pay package
By Tom Hals WILMINGTON (Reuters) -A Delaware judge tossed out Elon Musk’s record-breaking $56 billion Tesla pay package on Tuesday, calling the compensation granted by the EV maker’s board[...]
Read more
Fed shifted to rate cuts in 2019, but it took time to get there
By Howard Schneider WASHINGTON (Reuters) – U.S. Federal Reserve policymakers are expected to cut interest rates later this year, but like any policy turn made outside of a crisis the shift is ev[...]
Read more
Thermo Fisher forecasts 2024 below estimates, cautious on biotech demand
By Bhanvi Satija (Reuters) -Thermo Fisher Scientific on Wednesday forecast annual profit and revenue below Wall Street estimates, signaling that a slump in demand for its services used to make therapi[...]
Read more
Meta CEO Zuckerberg apologizes to parents at US Senate social media hearing
WASHINGTON (Reuters) – Meta Chief Executive Mark Zuckerberg on Wednesday apologized to families at a U.S. Senate hearing about the impact that social media has on children. Under prodding from R[...]
Read more
Mastercard profit beats estimates on healthy spending trends
By Niket Nishant (Reuters) -Mastercard beat Wall Street estimates for fourth-quarter profit on Wednesday, as the payments processor benefited from resilient consumer spending during the holiday shoppi[...]
Read more
Biogen drops Alzheimer’s drug Aduhelm, ending a 17-year chapter
(Reuters) -Biogen will end a post-approval study of Alzheimer’s treatment Aduhelm and return the licensing rights on the drug after failing to find a partner to mitigate costs of obtaining stand[...]
Read more